Generic drug maker Ozon Pharmaceuticals will hold an initial public offering on the Moscow Stock Exchange in October. Investors will be offered shares issued as part of the company’s additional issuance, according to a message on its website.
Author:
https://rb.ru/author/bmuzichenko/
Subscribe to RB.RU on Telegram
Ozon Pharmaceuticals, existing shareholders and their affiliates will enter into customary agreements that will limit the disposition of shares for a period of 180 days after the completion of the offering. There is also a stabilization mechanism for 30 days after the start of trading.
The IPO will be available to qualified and unqualified Russian investors, both individuals and domestic institutional investors.
The money raised will be used to develop the company, reduce its debt load and other general corporate objectives, according to the press release. In April, Vedomosti sources reported that the company could raise more than 10 billion rubles.
Ozon Pharmaceuticals was founded in 2001 in Zhigulevsk, Samara region. The company has no relationship with the Ozon market. According to the manufacturer’s own data, its portfolio includes more than 500 names of patented generic analogues.
In the first six months of 2024, the company’s revenue amounted to 12.6 billion rubles, and net profit – 2.9 billion rubles.
Author:
Bogdan Muzychenko
Source: RB
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.
